Bronstein, Gewirtz & Grossman, LLC Encourages Fortrea Holdings Inc. (FTRE) Shareholders to ...
NEW YORK CITY, NY / ACCESS Newswire / March 21, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims ...
FTRE股价触及52周低点8.94美元，年度跌幅显著
Investing.com — Fortrea Holdings (NASDAQ: FTRE )股价已触及52周低点，交易价格为8.94美元，投资者对该公司充满挑战的一年做出反应。根据 InvestingPro 数据，该股票的技术指标显示超卖状态，而分析师维持10美元至15.50美元的目标价，表明存在上涨潜力。最新价格水平反映了与之前时期相比的显著下滑，该股票一年内变化急剧，暴跌77.65%。这一 ...
Bronstein, Gewirtz & Grossman, LLC Is Investigating Fortrea Holdings Inc. (FTRE) And ...
NEW YORK CITY, NY / ACCESS Newswire / March 20, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims ...
Candidate Q&A: Cottage Grove village president
Other public service: Cottage Grove village trustee, 2015-2019; Cottage Grove Dementia Friendly Coalition Committee member; ...
Fortrea’s credit rating downgraded by Fitch due to weakening profile
Fitch predicts a 7.3% decline in Fortrea’s revenues in 2025 and expects revenue growth to return in 2026 within the 3.0% to 4.0% range. The company’s inconsistent revenue growth and uncertain ...
Fortrea Holdings运营总监出售价值4,980美元普通股
Fortrea Holdings Inc.（纳斯达克代码：FTRE）首席运营官Mark A. Morais近期出售了该公司价值4,980美元的普通股。这家市值约8.95亿美元的临床研究机构的股票交易发生在2025年3月12日，平均售价为9.98美元，接近该股52周低点9.55美元。根据 InvestingPro ...
Clinical Trial Services Market worth US$101.86 billion by 2030 with 8.9% CAGR ...
The global Clinical Trial Services Market, valued at US$60.76 billion in 2024, is forecasted to grow at a robust CAGR of 8.9% ...
Fortrea Holdings Inc. (NASDAQ:FTRE) Receives Consensus Recommendation of “Reduce” from ...
Fortrea Holdings Inc. (NASDAQ:FTRE – Get Free Report) has received a consensus rating of “Reduce” from the twelve analysts ...
William Blair Has Pessimistic Outlook of Fortrea Q4 Earnings
Research analysts at William Blair cut their Q4 2025 earnings estimates for Fortrea in a research report issued to clients and investors on Monday, March 3rd. William Blair analyst M. Smock now ...